Open access
Open access
Powered by Google Translator Translator

Vaccines

J&J COVID-19 Vaccine: FDA recommends booster shot for all adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.

17 Oct, 2021 | 21:32h | UTC

News release: Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee

Commentaries:

FDA panel endorses booster shot for J&J COVID-19 vaccine – Associated Press

The Johnson & Johnson one-dose vaccine offers good protection now. A booster shot will maximize that, experts say – CNN

FDA advisers recommend J&J Covid-19 vaccine boosters, talk mix and match boosters – CNN

Related: [Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.

 


[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

17 Oct, 2021 | 21:29h | UTC

Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – medRxiv

Related:

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

 

Commentary on Twitter

 


Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines.

17 Oct, 2021 | 21:27h | UTC

News release: Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines – Beth Israel Deaconess Medical Center

Original study: Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines – New England Journal of Medicine

 

Commentary on Twitter

 


Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

15 Oct, 2021 | 02:49h | UTC

Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report – medRxiv

Commentary: Study: Mixing and Matching COVID-19 Booster Shots Is Effective, Safe – U.S. News

 

Commentary on Twitter

 


Perspective | Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines.

15 Oct, 2021 | 02:44h | UTC

Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines – JAMA

 


FDA panel green-lights Moderna COVID boosters for risk groups.

15 Oct, 2021 | 02:43h | UTC

FDA panel green-lights Moderna COVID boosters for risk groups – CIDRAP

 


Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.

15 Oct, 2021 | 02:41h | UTC

Covid-19 treatments and vaccines must be evaluated in pregnancy – The BMJ

Related:

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

 

Commentary on Twitter

 


Cohort study: Vaccinated pregnant patients had 90% lower risk of severe or critical Covid-19 compared with unvaccinated pregnant patients.

15 Oct, 2021 | 02:38h | UTC

Maternal Outcomes After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Vaccinated Compared With Unvaccinated Pregnant Patients – Obstetrics & Gynecology

Related:

Two observational studies suggest spontaneous abortion is not increased following COVID-19 mRNA vaccination during pregnancy.

Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.

5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.

CDC Guidance: Pregnant people should be vaccinated against COVID-19.

ACOG and SMFM Recommend COVID-19 Vaccination for Pregnant Individuals – “ACOG encourages its members to enthusiastically recommend vaccination to their patients.”

Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

 

Commentary on Twitter (thread – click for more)

 


[Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients.

14 Oct, 2021 | 10:17h | UTC

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – medRxiv

Commentary: Novel vaccine demonstrates high efficacy for prevention of COVID-19 – News Medical

Related:

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

 

Commentary on Twitter

 


How Covax failed on its promise to vaccinate the world – “Covax, described as “naively ambitious” by one expert, has contributed just 5% of all vaccines administered globally”.

14 Oct, 2021 | 10:12h | UTC

How Covax failed on its promise to vaccinate the world – The Bureau of Investigative Journalism

Related:

Perspective | A beautiful idea: how COVAX has fallen short.

WHO Launches Strategy to Achieve Global Covid-19 Vaccination by mid-2022.

WHO special envoys: To beat Covid, there’s a simple lesson – no one’s safe until everyone’s safe.

Joint COVAX Statement on the Equal Recognition of Vaccines – COVAX urges all government authorities to recognize as fully vaccinated all people who have received COVID-19 vaccines that have been deemed safe and effective by WHO.

WHO COVAX Joint Statement: Call to action to equip COVAX to deliver 2 billion doses in 2021.

Covax: How will Covid vaccines be shared around the world?

 


WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups.

13 Oct, 2021 | 01:48h | UTC

WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups – CIDRAP

See also: WHO advises additional COVID shot for immunocompromised people – Reuters

 


Nationwide study in Sweden shows link between COVID vaccination and reduced household transmission.

12 Oct, 2021 | 00:25h | UTC

News release: Nationwide study shows link between COVID vaccination and reduced household transmission – Umea University

Original study: Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members – JAMA Internal Medicine

Related:

Review | Prevention of host-to-host transmission by SARS-CoV-2 vaccines.

Study ties COVID vaccines to lower transmission rates.

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose

Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

 


Bioethics | The Trolley Problem and Vaccinating Young People Against COVID-19.

10 Oct, 2021 | 21:50h | UTC

The Trolley Problem and Vaccinating Young People Against COVID-19 – Science-Based Medicine

 


Heart-inflammation risk from Pfizer COVID vaccine is very low.

10 Oct, 2021 | 21:42h | UTC

Heart-inflammation risk from Pfizer COVID vaccine is very low – Nature

Original studies:

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

 


Study shows an increased risk of Guillain-Barré Syndrome with the J&J vaccine; the estimated observed to expected rate ratio was 4.18 for the 42-day window.

8 Oct, 2021 | 10:40h | UTC

Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021 – JAMA

 

Commentary on Twitter

 


Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

8 Oct, 2021 | 10:29h | UTC

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England – Eurosurveillance

Related:

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 


Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

7 Oct, 2021 | 10:55h | UTC

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar – New England Journal of Medicine

Related: Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

 

Commentary on Twitter

 


Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

7 Oct, 2021 | 10:51h | UTC

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization – New England Journal of Medicine

Commentary: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD

Related Study: Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine

 

Commentaries on Twitter

 


Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

7 Oct, 2021 | 10:49h | UTC

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine

Commentary: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD

Related study: Myocarditis after Covid-19 Vaccination in a Large Health Care Organization – New England Journal of Medicine

 

Commentaries on Twitter

 


Perspective | No one is safe until we are all safe.

7 Oct, 2021 | 10:47h | UTC

No one is safe until we are all safe – Science Translational Medicine

Commentary: Covid ‘still running rampant’ worldwide, warns creator of Oxford vaccine – The Guardian

Related: Opinion: Vaccine Nationalism Harms Everyone and Protects No One

 

Commentary on Twitter

 


Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups.

7 Oct, 2021 | 10:45h | UTC

Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups – Reuters

 


WHO approves first ever malaria vaccine for children at risk.

7 Oct, 2021 | 10:40h | UTC

WHO recommends groundbreaking malaria vaccine for children at risk – World Health Organization

Commentaries:

WHO Approves First Ever Malaria Vaccine – Health Policy Watch

A historic day for malaria – reaction to WHO decision on the RTS,S vaccine – London School of Hygiene & Tropical Medicine

In major decision, WHO recommends broad rollout of world’s first malaria vaccine – STAT

Why the WHO approval of the first malaria vaccine is a big deal – Vox

WHO greenlights the world’s first malaria vaccine — but it’s not a perfect shot – NPR

The World Health Organization Just Endorsed The World’s First Malaria Vaccine – TIME

WHO Backs Widespread Use Of First Malaria Vaccine – Forbes

World’s 1st malaria vaccine recommended by WHO – LiveScience

 

Commentaries on Twitter

(thread – click for more)

 


EMA recommendations on extra doses and boosters of BioNTech/Pfizer and Moderna mRNA vaccines.

6 Oct, 2021 | 10:15h | UTC

Comirnaty and Spikevax: EMA recommendations on extra doses and boosters – European Medicines Agency

Related: The difference between COVID-19 ‘third doses’ and ‘boosters’ – Emory News Center

 

Commentary on Twitter

 


Supplement: Triumphs of Vaccination.

6 Oct, 2021 | 08:55h | UTC

Homepage: Triumphs of Vaccination – The Journal of Infectious Diseases

Triumphs of Immunization

Pertussis (Whooping Cough)

Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease

The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease

Hepatitis B Vaccines

Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe

Rubella Eradication: Not Yet Accomplished, but Entirely Feasible

Human Papillomavirus Vaccines

Smallpox

Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster

Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication

Influenza Vaccines: Successes and Continuing Challenges

Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination

Herpes Zoster Vaccines

Overview of the United States’ Immunization Program

The World of Immunization: Achievements, Challenges, and Strategic Vision for the Next Decade

 


Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

5 Oct, 2021 | 10:09h | UTC

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study – The Lancet

Commentary: Expert reaction to study on Pfizer-BioNTech vaccine effectiveness up to 6 months – Science Media Centre

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.